[
  {
    "ts": null,
    "headline": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=8254915e7670afe8b6a069928e55faeefab2dc8bf3aa724d4abdd3a742446c1d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757524020,
      "headline": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136725939,
      "image": "",
      "related": "DGX",
      "source": "MarketWatch",
      "summary": "Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=8254915e7670afe8b6a069928e55faeefab2dc8bf3aa724d4abdd3a742446c1d"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript",
    "summary": "Get the latest insights from Quest Diagnostics at the 2025",
    "url": "https://finnhub.io/api/news?id=ab1d9cde3c21e1b4eeb38584de2782d1aabe5bfa02cae7a7fc14546b1c7824b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757510189,
      "headline": "Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript",
      "id": 136685345,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "DGX",
      "source": "SeekingAlpha",
      "summary": "Get the latest insights from Quest Diagnostics at the 2025",
      "url": "https://finnhub.io/api/news?id=ab1d9cde3c21e1b4eeb38584de2782d1aabe5bfa02cae7a7fc14546b1c7824b5"
    }
  },
  {
    "ts": null,
    "headline": "Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test",
    "summary": "MADISON, Wis., September 10, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when trea",
    "url": "https://finnhub.io/api/news?id=41c2fc32ecc45fec540a5c08446ff5bc85bea04d909ce428fc52f673fd2bc44e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757503800,
      "headline": "Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test",
      "id": 136693119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "MADISON, Wis., September 10, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when trea",
      "url": "https://finnhub.io/api/news?id=41c2fc32ecc45fec540a5c08446ff5bc85bea04d909ce428fc52f673fd2bc44e"
    }
  }
]